Lab-grown heart cells injected into failing hearts: a new hope?

NCT ID NCT07347197

Not yet recruiting Disease control Sponsor: Heartseed Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial will test whether injecting lab-grown heart muscle cells (made from stem cells) into the heart can safely help people with severe heart failure. Fourteen participants with weak hearts will receive the cells via a catheter. The main goal is to check for side effects over 26 weeks, while also measuring whether heart function improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Human iPS-cell-derived cardiomyocyte spheroids (HS-001CS) injected into the heart
What this could lead to: If it works, this could point toward a new way to repair damaged heart muscle and improve heart function in people with severe heart failure.
What could go wrong: This is an early, small trial (14 people) testing safety first. The cells may not survive or integrate, and there are risks from the injection procedure and potential immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY (DCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy heart failure myocardial ischemia systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DILATED CARDIOMYOPATHY (DCM) HEART FAILURE ISCHEMIC HEART DISEASE ISCHEMIC HEART FAILURE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.